TMCnet News
Global Market Report From IDTechEx Research on Tissue Engineering 2018-2028: Technologies, Markets, ForecastsBOSTON, Jan. 31, 2019 /PRNewswire/ -- Tissue engineering, referring to the technologies that use physical, chemical, biological and engineering processes to control and direct the aggregate behavior of cells, has become a field of increasing commercial interest. Though tissue engineering as a field has been around since the late 1970s, there have been few commercial successes. However, human understanding of biology, and our ability to manipulate it has finally reached a point where complex living tissue equivalents are being developed. The IDTechEx Research report Tissue Engineering 2018-2028: Technologies, Markets, Forecasts investigates this next generation of tissue engineering products and their potential in the next 10 years. This report covers living tissue equivalents which contain both living cells and a 3D structure. Applications The biggest applications for engineered tissues are in research and development, and in medicine. This report discusses the following key applications of tissue engineering:
Clinical Landscape A chapter of Tissue Engineering 2018-2028: Technologies, Markets, Forecasts is dedicated to the use of tissue engineering products in medicine. The following classes of tissue engineered therapies are highlighted:
Additionally, a summary of ongoing clinical trials of tissue engineered products is provided, organized by trial phase, tissue type, and sponsor. The rest of this chapter describes and discusses the dynamics of US and EU markets, with a look at relevant regulatory pathways, exemptions, and loopholes for tissue engineered products, as well as speculations on the future of regulating this novel class of therapy. Market Forecasts A market forecast for tissue engineered products is provided for the years 2018 - 2028, where the total value for tissue engineered products is predicted to surpass $4.8 billion. This market is broken down into key applications of therapies (clinical use) and tissue models (research use). Key players in both applications are presented, and the value chain and relevant business models are discussed. Separately, a forecast for 3D bioprinters, an up-and-coming technology for tissue engineering, is also provided for the years 2018 - 2028. Technology A wide range of approaches are still being explored in tissue engineering, and this report covers both the most innovative and cutting-edge techniques as well as more established technologies. Technologies presented in Tissue Engineering 2018-2028: Technologies, Markets, Forecasts are:
For more information contact the IDTechEx Research team at [email protected] or visit www.IDTechEx.com/tissue. IDTechEx guides your strategic business decisions through its Research, Consultancy, and Events services, helping you profit from emerging technologies. Find out more at www.IDTechEx.com. Table of Contents Tissue Engineering 2018-2028: Technologies, Markets, Forecasts 1. EXECUTIVE SUMMARY 1.1. Overview 1.2. What is Tissue Engineering? 1.3. How are Tissues Engineered? 1.4. Key Players 1.5. Key Drivers 1.6. Key Opportunities 1.7. Tissue Engineered Products Market Forecast 2018 - 2028 1.8. Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028 1.9. Tissue Engineered Products for Research Use Market Forecast 2018 - 2028 1.10. Key Technologies 1.11. Key Challenges 2. INTRODUCTION 2.1. Report Scope 2.2. Advantages of 3D Cell Culture 2.3. Key Driver: Regenerative Medicine 2.4. Key Driver: Unmet Need in Organs for Transplant 2.5. Key Driver: Product Testing in Medicine 2.6. Key Driver: Avoiding Costly Drug Trial Failures 2.7. Key Driver: Product Testing in Consumer Products 2.8. Current Challenges: Biological 2.9. Current Challenges: Commercialization 2.10. Tissue Engineering in 2017 3. KEY OPPORTUNITIES 3.1. Overview 3.2. Testing of Cosmetics and Other Consumer Goods 3.3. Product Testing: Companies 3.4. Product Testing: 3.5. Drug Screening: Dermagenist 3.6. Drug Screening: Drug Development Process 3.7. Drug Screening: Benefits of Tissue Engineering 3.8. Drug Screening: Cancer 3.9. Drug Screening: Organ-on-a-chip 3.10. Drug Screening: Companies 3.11. Personalised Medicine 3.12. Cell-Based Biosensors 3.13. Food and Other Animal Products 3.14. Esthetics 4. TISSUE ENGINEERING CLINICAL LANDSCAPE 4.1. Overview 4.2. Regenerative Medicine 4.3. Competing Products 4.4. Competing Products: Advantages and Disadvantages 4.5. Commercial Activity 4.6. The US Market 4.7. Products with FDA Marketing Approval 4.8. The European Market 4.9. Clinical Trials 4.10. Clinical Trials: By Indication and Phase 4.11. Skin: Clinical Products 4.12. Cartilage: Clinical Products 4.13. Cartilage: NeoCart 4.14. Pre-Clinical Products 4.15. Regulatory Exemptions 4.16. Hospital Exemption Scheme 4.17. Hospital Exemption Scheme: Problems 4.18. 21st Century Cures Act and the Regenerative Medicine Advanced Therapy Designation 4.19. Orphan Drug Designation 4.20. Scams and Unauthorized Treatments 4.21. Moving to Conditional Approval 4.22. Moving to Conditional Approval: Case Study 4.23. Learning from Medical Innovations 4.24. Future 5. MARKETS AND FORECASTS 5.1. Overview 5.2. Market Barriers 5.3. Tissue Engineering Value Chain 5.4. Tissue Engineering Value Chain: Discussion 5.5. Forecasts 5.6. Tissue Engineered Products Market Forecast 2018 - 2028 5.7. Companies with Marketed Clinical Products 5.8. Companies Developing Engineered Tissues for Clinical Use 5.9. Business Models: Engineered Autologous Tissues 5.10. Business Models: Cryopreserved Allogeneic Tissues 5.11. Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028 5.12. Companies Engineering Tissues for Research Use 5.13. Business Models: Tissues for Research Use 5.14. Tissue Engineered Products for Research Use Market Forecast 2018 - 2028 5.15. Companies Producing Organ-On-A-Chips 5.16. Companies Producing Lab-Grown Meat 5.17. Scaffold Manufacturers 5.18. 3D Bioprinter Market and Forecasts 5.19. Growing 3D Bioprinting Market 5.20. 3D Bioprinting Value Chain 5.21. 3D Bioprinting Value Chain: Discussion 5.22. 3D Bioprinters by Cost and Technology 5.23. 3D Bioprinter Market Forecast 2018 - 2028 5.24. Caveats 6. TISSUE ENGINEERING TECHNOLOGIES 6.1. Overview 7. ESTABLISHED TECHNOLOGIES 7.1. Introduction 7.2. Semi-Permeable Membranes 7.3. Key Semi-Permeable Membrane Manufacturers 7.4. Hydrogels 7.5. Cell-Laden Hydrogels 7.6. Cell-Laden Hydrogels: Companies 7.7. Cell-Laden Hydrogels: SWOT Analysis 8. 3D BIOPRINTING 8.1. Introduction 8.2. 3D Bioprinting Process 8.3. Comparison of Key Specifications 8.4. 3D Bioprinting Technology Comparison 8.5. Inkjet: Thermal 8.6. Inkjet: Piezoelectric 8.7. Inkjet: Companies 8.8. Inkjet: SWOT Analysis 8.9. Extrusion: Pneumatic 8.10. Extrusion: Mechanical 8.11. Extrusion: Companies 8.12. Extrusion: Example 8.13. Extrusion: SWOT Analysis 8.14. LIFT: Laser-Induced Forward Transfer 8.15. LIFT: Companies 8.16. LIFT: SWOT Analysis 8.17. Microvalve: Solenoid 8.18. Microvalve: Companies 8.19. Microvalve: SWOT Analysis 8.20. Industry-wide Technical Challenges 8.21. The Ideal 3D Bioprinter 8.22. Animal Studies 8.23. Future Technological Directions 9. SCAFFOLD TECHNOLOGIES 9.1. Tissue Engineering Scaffolds 9.2. Ideal Scaffold 10. 3D PRINTING 10.1. Introduction 10.2. Examples of 3D Printed Medical Products 10.3. Thermoplastic Extrusion 10.4. Thermoplastic Extrusion: Example 10.5. Thermoplastic Extrusion: Key Manufacturers 10.6. Thermoplastic Extrusion: SWOT Analysis 10.7. Material Jetting 10.8. Material Jetting: Key Players 10.9. Material Jetting: SWOT Analysis 10.10. Stereolithography 10.11. Stereolithography: Key Players 10.12. Stereolithography: SWOT Analysis 10.13. Stereolithography: Microstereolithography 10.14. Stereolithography: Projection 10.15. Stereolithography: Multiphoton Lithography 10.16. Stereolithography: Multiphoton Lithography: Example 10.17. Selective Laser Sintering 10.18. Selective Laser Sintering: Key Players 10.19. Selective Laser Sintering: SWOT Analysis 11. DECELLULARIZED ORGANS 11.1. Introduction 11.2. History 11.3. Decellularization 11.4. Recellularization 11.5. Companies 11.6. Future Technological Directions 11.7. Bioreactors 12. OTHER SCAFFOLD TECHNOLOGIES 12.1. Introduction 12.2. Phase Separation 12.3. Freeze-Drying 12.4. Freeze-Drying: Companies 12.5. Solvent Casting and Particle Leaching 12.6. Gas Foaming 12.7. Chemical Processes: Strengths and Weaknesses 12.8. Textile Technologies 12.9. Electrospinning 12.10. Cell Electrospinning 12.11. Electrospinning: Examples 12.12. Electrospinning: SWOT Analysis 12.13. Melt Electrospinning 12.14. Melt Electrospinning: SWOT Analysis 12.15. Electrospinning: Companies 13. SCAFFOLDLESS TECHNOLOGIES 13.1. Introduction 13.2. Cell Spheroids 13.3. Cell Spheroids: Self-Assembly 13.4. Cell Spheroids: Self-Organization 13.5. Cell Spheroids: Rotational Culture Equipment 13.6. Cell Spheroids: Key Companies 13.7. Cell Sheets 13.8. Cell Therapy Devices 13.9. Cell Therapy Devices: Companies 14. TISSUE ENGINEERING CHALLENGES 14.1. Industry-Wide Technical Challenges 14.2. Biopreservation 14.3. Vascularization 15. COMPANY PROFILES 15.1. 3D Bioprinting Solutions/ Vivax Bio 15.2. 3D Biotek 15.3. 3Dynamic Systems Ltd 15.4. Aether Inc. 15.5. Aspect Biosystems 15.6. ATERA 15.7. Avery Therapeutics 15.8. AxoSim 15.9. BioBots 15.10. BioDan Group 15.11. BIOLIFE4D 15.12. Cellenion SASU 15.13. Cellf BIO 15.14. Cellink 15.15. CUTISS 15.16. Digilab Inc. 15.17. GeSiM 15.18. Hesperos 15.19. Histogenics 15.20. Lena Biosciences 15.21. Microdrop Technologies GmbH 15.22. MicroFab Technologies 15.23. Mimetas 15.24. PeptiGel Design Ltd 15.25. Poietis 15.26. Prellis Biologics 15.27. Regemat 3D 15.28. RegenHU 15.29. SE3D 15.30. Sichuan Revotek Co. Ltd. 15.31. Synthecon 15.32. Tara Biosystems 15.33. TissUse 15.34. Upside Biotechnologies Media Contact: Related Links View original content:http://www.prnewswire.com/news-releases/global-market-report-from-idtechex-research-on-tissue-engineering-2018-2028-technologies-markets-forecasts-300787596.html SOURCE IDTechEx |